Alnylam posted its first-ever GAAP profit in 2025, reporting $314 million in net income. Amvuttra’s rapid ATTR-CM expansion drove the turnaround, though Q4 sales modestly missed expectations. Meanwhile, competitive pressure from Pfizer and BridgeBio is reshaping the ATTR-CM landscape. and pricing dynamics and early-year volatility may weigh on near-term performance despite strong full-year guidance.